Analysts forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will post $890,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Spero Therapeutics’ earnings, with the highest sales estimate coming in at $1.28 million and the lowest estimate coming in at $400,000.00. Spero Therapeutics posted sales of $990,000.00 during the same quarter last year, which suggests a negative year-over-year growth rate of 10.1%. The company is scheduled to announce its next earnings results on Monday, April 1st.

According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $3.20 million for the current financial year, with estimates ranging from $2.67 million to $3.55 million. For the next year, analysts expect that the firm will post sales of $11.80 million, with estimates ranging from $7.50 million to $18.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.04. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%. The firm had revenue of $0.66 million for the quarter, compared to the consensus estimate of $0.66 million.

A number of equities research analysts have weighed in on SPRO shares. Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 10th. Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price target on the stock in a research note on Friday, October 19th. Bank of America downgraded shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $19.00 to $9.00 in a research note on Tuesday, October 16th. Finally, Cantor Fitzgerald set a $27.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $21.58.

Several large investors have recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $462,000. EcoR1 Capital LLC acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $9,383,000. Aquilo Capital Management LLC boosted its stake in shares of Spero Therapeutics by 91.9% in the 3rd quarter. Aquilo Capital Management LLC now owns 799,691 shares of the company’s stock valued at $8,405,000 after purchasing an additional 383,000 shares in the last quarter. Highland Capital Management LP acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $210,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $126,000. Institutional investors own 43.58% of the company’s stock.

SPRO traded down $0.02 during trading on Thursday, reaching $7.77. 139,593 shares of the company’s stock were exchanged, compared to its average volume of 82,263. Spero Therapeutics has a fifty-two week low of $7.18 and a fifty-two week high of $19.00. The company has a market capitalization of $140.95 million and a P/E ratio of -0.44.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Featured Article: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.